These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14621840)

  • 41. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
    J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients.
    Opelz G; Naujokat C; Daniel V; Terness P; Döhler B
    Transplantation; 2006 May; 81(9):1227-33. PubMed ID: 16699447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients.
    Frey DJ; Matas AJ; Gillingham KJ; Canafax D; Payne WD; Dunn DL; Sutherland DE; Najarian JS
    Transplantation; 1992 Jul; 54(1):50-6. PubMed ID: 1631944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.
    Chiu A; Landsberg D; Cameron EC; Manson AD; Shackleton C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1039-40. PubMed ID: 1899146
    [No Abstract]   [Full Text] [Related]  

  • 45. Cancer risk associated with ATG/OKT3 in renal transplantation.
    Hibberd AD; Trevillian PR; Wlodarzcyk JH; Gillies AH; Stein AM; Sheil AG; Disney AP
    Transplant Proc; 1999; 31(1-2):1271-2. PubMed ID: 10083567
    [No Abstract]   [Full Text] [Related]  

  • 46. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period.
    Hesse UJ; Wienand P; Baldamus C; Arns W
    Transplant Proc; 1990 Oct; 22(5):2273-4. PubMed ID: 2120814
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 48. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation.
    Portela D; Patel R; Larson-Keller JJ; Ilstrup DM; Wiesner RH; Steers JL; Krom RA; Paya CV
    J Infect Dis; 1995 Apr; 171(4):1014-8. PubMed ID: 7706779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monoclonal antibodies in renal transplantation: a review.
    Parlevliet KJ; Schellekens PT
    Transpl Int; 1992 Sep; 5(4):234-46. PubMed ID: 1418316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors.
    Ohshima S; Fujita T; Ono Y; Kinukawa T; Katoh N; Matsuura O
    Artif Organs; 1996 Oct; 20(10):1130-6. PubMed ID: 8896734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
    Cecka JM; Gjertson D; Terasaki PI
    Transplant Proc; 1993 Feb; 25(1 Pt 1):548-9. PubMed ID: 8438408
    [No Abstract]   [Full Text] [Related]  

  • 52. [Immunosuppressive therapy in renal transplantation].
    Nakamura H
    Nihon Hinyokika Gakkai Zasshi; 1993 Aug; 84(8):1359-84. PubMed ID: 8411796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
    Wilde MI; Goa KL
    Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
    Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR
    Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA.
    Lloveras J; Puig JM; Oliveras A; Orfila A; Comerma I; Aubia J; Masramón J
    Transplant Proc; 1992 Feb; 24(1):43-4. PubMed ID: 1539335
    [No Abstract]   [Full Text] [Related]  

  • 59. Renal transplantation at the Washington Hospital Center: experience with OKT3 and Minnesota antilymphoblast globulin for induction of immunosuppression.
    Jonsson J; Light JA; Korb SM
    Clin Transpl; 1990; ():275-88. PubMed ID: 2129409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
    Carrier M; Jenicek M; Pelletier LC
    Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.